Genetic predictors of coronary heart disease risk factors in premenopausal African-American women

Ethnicity and Disease

Volumn 15, Issue 2, 2005, Pages 221-232

  Giger, Joyce Newman ^a   Strickland, Ora L ^d   Weaver, Michael ^b   Taylor, Herman ^e   Acton, Ronald T ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

^d EMORY UNIVERSITY   (United States)

^e UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

African American women; Coronary heart disease risk factors; Genotypes; Metabolic syndrome; Phenotypes; Premenopausal

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; ENDOTHELIN 1; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; INSULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AFRICAN AMERICAN; ARMY; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; BODY WEIGHT; CHI SQUARE TEST; COHORT ANALYSIS; COMMUNITY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIET RESTRICTION; DNA EXTRACTION; DNA POLYMORPHISM; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLIC SYNDROME X; MICROSATELLITE MARKER; MORTALITY; OBESITY; POLYMERASE CHAIN REACTION; PREMENOPAUSE; RISK FACTOR; STANDARDIZATION; SYSTOLIC BLOOD PRESSURE; TELOMERE;

ADULT; AFRICAN AMERICANS; ALABAMA; APOLIPOPROTEINS E; CASE-CONTROL STUDIES; CORONARY DISEASE; FEMALE; GENE FREQUENCY; GEORGIA; HUMANS; INSULIN RESISTANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PREMENOPAUSE; RISK FACTORS; WOMEN'S HEALTH;

EID: 17744390382     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (98)

1. American Heart Association (AHA). 2002 Heart and Stroke: Statistical Update. Dallas, Tex: AHA; 2002.
2. National Center for Health Statistic (NCHS). Health, United States, 2003 and Injury Chartbook. Hyattsville, Md: NCHS; 2003.
3. Gillum R, Grant C. Coronary heart disease in Black populations, II: risk factors. Am Heart J. 1982;104:852-864.
4. Gillum R, Liu K. Coronary heart disease mortality in the United States Blacks; 1940-1978: trends and unanswered questions. Am Heart J. 1984;108:728-732.
5. Kasi S. Social and psychological factors in etiology of coronary heart disease in Black populations: an exploration of research needs. Am Heart J. 1984;108:660-668.
6. Giger J, Davidhizar R. Transcultural Nursing: Assessment and Intervention. 4th ed. St. Louis, Mo: Mosby Yearbook, Inc; 2004.
7. Giger J, Davidhizar R, Johnson J, Poole V. Health promotion in ethnic minorities. Rehabil Nurs. 1997;11(6):303-307, 310, 336.
8. Keller C, Fleury J, Bergstrom DL. Risk factors for coronary heart disease in African-American women. Cardiovasc Nurs. 1995; 31(2):9-13.
9. Francis C. Research in coronary heart disease in Blacks. Issues and challenges. J Health Care Poor Underserved. 1997;8(3):250-269.
10. Smith N, Croft J, Heath A, Cokkinides V. Changes in cardiovascular disease knowledge and behavior in a low-education population of African-American and White adults. Ethn Dis. 1996;6(3-4):244-254.
11. Iannotti RJ, Zuckerman AE, Rifai N. Correlations of cardiovascular disease risk factors between African-American siblings. J Pediatr. 2000;136:111-119.
12. Tiret L. Gene-environment interaction: a central concept in multifactorial diseases. Proc Nutr Soc. 2002;61(4):457-463.
13. Breslow JL. Genetic markers for coronary heart disease. Clin Cardiol. 2001;24(suppl 7): II-14-II-17.
14. Strittmatter WJ, Bova Hill C. Molecular biology of apolipoprotein E. Curr Opin Lipidemiol. 2002;13(2):119-123.
15. Schaefer EJ. Lipoproteins, nutrition, and heart disease. Am J Clin Nutr. 2002;75(2): 191-212.
16. Kolovou G, Daskalova D, Mikhailidis DP. Apolipoprotein E polymorphism and atherosclerosis. Angiology. 2003;54(1):59-71.
17. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a huge review. Am J Epidemiol 2002; 155:487-495.
18. Acton RT. The major histocompatability complex. In: Rich RR, Fleisher TA, Shearer WT, Kotzin BL, Schroeder HW Jr, eds. Clinical Immunology Principles and Practice. 2nd ed. Vol 1. London: Mosby International Ltd; 2001-ap6:6.1-6.13.
19. Acton RT, Go RCP, Roseman JM. Review of the evidence that immunogenetic factors are involved in the etiology of atherosclerosis. Monographs Hum Genet. 1992;14:253-271.
20. Hansson GK. Regulation of immune mechanisms in atherosclerosis. Ann N Y Acad Sci. 2001;947:157-166.
21. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-126.
22. Elghannam H, Tavackoli S, Ferlic L, Gotti AM, Ballantyne CM, Marian AJ. A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy. J Mol Med. 2000;78:562-568.
23. Kovalev YP, Dzeranova NY, Servova LD, Litmanovich KY, Ziskina RA, Rudenko DI. Comparison of HLA antigene spectrum in atherosclerosis of various location. Coron Vasc. 1990;32:118-125.
24. Stone PH, Sherrid MV, Cohn KE. Correlation of HLA types in premature coronary artery disease: an attempt to define independent genetic risk factors. Chest. 1981;79:381-385.
25. Osa A, Almenar L, Palencia M, Puig N, Chirivella M, Montoro J. Antigens of the major histocompatibility system in ischemic heart disease and idiopathic dilated cardiomyopathy. Clin Cardiol. 1999;22:292-296.
26. Limas CJ, Limas C. HLA-DRw6 antigen in chronic congestive heart failure secondary to coronary artery disease (ischemic cardiomyopathy). Am J Cardiol. 1988;62:816-818.
27. Polyanskaya IS, Alekseev LP, Yazdovskii VV. Human leukocyte antigens as markers of predisposition to ischemic heart disease in Russian and Georgian populations. Biomed Sci. 1990;1:639-641.
28. Acton RT, Bell DSH, Go RCP, Roseman JM, Tseng M-L, Louv W. The association of HLA phenotypes with hypertension in African Americans and Caucasoid Americans with type II diabetes, a population at risk for renal disease. Transplant Proc. 1993;25:2400-2403.
29. Acton RT, Roseman JM, Bell DSH, et al. Genes within the major histocompatibility complex predict NIDDM in African-American women in Alabama. Diabetes Care. 1994; 17:1491-1494.
30. Acton RT, Bell DSH, Collins J, et al. Genes within and flanking the major histocompatibility region are risk factors for diabetes, insulin resistance, hypertension, and microalbuminuria in African-American Women. Transplant Proc. 1997;29:3710-3712.
31. Acton RT, Bell DSH, Go RCP, Roseman JM, Tseng M-L, Louv W. The association of HLA phenotypes with hypertension in African Americans and Caucasoid Americans with type II diabetes, a population at risk for renal disease. Transplant Proc. 1993;25:2400-2403.
32. Hajeer AH, Hutchinson TV. TNF-α gene polymorphism: clinical and biological implications. Microsc Res Tech. 2000;5:216-228.
33. Juhan-Vague I, Morange PE, Alessi MC. The insulin resistance syndrome: implications for thrombosis and cardiovascular disease. Pathophysiol Haemost Thromb. 2002;32(5-6):269-273.
34. Pociot F, Brisnt L, Jongeneel CV, et al. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol. 1993;23:224-231.
35. Derkx HHF, Bruin CV, Jongneel LP, et al. Familial differences in endotoxin-induced TNF release in whole blood mononuclear cells in vitro: relationship to TNF gene polymorphism. J Endotoxin Res. 1995;2:19-25.
36. Jovinge S, Hamsten A, Tornvall P, et al. Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism 1998;47:113-118.
37. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E, for the Cholesterol and Recurrent Events (CARE) Investigators. Elevation of tumor necrosis factor-alpha increased risk of recurrent coronary events after myocardial infection. Circulation. 2000;101: 2149-2153.
38. Elghannam H, Tavackoli S, Ferlic L, Gotto A Jr, Ballantyne CM, Marian AJ. A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy. J Mol Med. 2000;78:562-568.
39. Szalai C, Fust G, Duba J, et al. Association of polymorphisms and allelic combinations in the tumor necrosis factor-alpha-complement MHC region with coronary artery disease. J Med Genet. 2002;39:46-51.
40. Luscher TF, Tanner FC, Tschudi MR, Noll G. Endothelial dysfunction in coronary artery disease. Annu Rev Med. 1993;44:395-418.
41. Wolpert HA, Steen SN, Istfan NW, Simonson DC. Insulin modulates circulating endothelin-1 levels in humans. Metabolism. 1993; 42:1027-1030.
42. Schiffrin EL, Deng LY, Sventek P, Day R. Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension. J Hypertens. 1997;15:57-63.
43. Agapitov AV, Haynes WG. Role of endothelin in cardiovascular disease. J Renin Angiotensin Aldosterone Syst. 2002;3:1-15.
44. Kalogeropoulou K, Mortzos G, Migdalis I, et al. Carotid atherosclerosis in type 2 diabetes mellitus: potential role of endothelin-1, lipoperoxides, and prostacyclin. Angiology. 2002; 53:279-285.
45. Teerlink JR. The role of endothelin in the pathogenesis of heart failure. Curr Cardiol Rep. 2002;4:201-212.
46. Arinami T, Ishikawa M, Inoue A, et al. Chromosomal assignments of the human endothelin family genes: the endothelin-1 gene (EDN1) to 6p23-p24, the endothelin-2 gene (EDN2) to 1p34, and the endothelin-3 gene (EDN3) to 20q13.2-q13.3. Am J Hum Genet. 1991;48:990-996.
47. Litt M, Luty JA. Dinucleotide repeat polymorphism at the D6S89 locus. Nucleic Acids Res. 1990;18:4301.
48. Hoehe MR, Ehrenreich H, Otterud B, et al. The human endothelin-1 gene (EDN-1) encoding a peptide with potent vasoactive properties maps distal to HLA on chromosome arm 6p in close linkage to D6S89. Cytogenet Cell Genet. 1993;62:131-135.
49. Reaven GM. Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia, and coronary heart disease. Am Heart J. 1991;121:1283-1288.
50. Owerbach D, Bell GI, Rutter WJ, Brown JA, Shows TB. The insulin gene is located on the short arm of chromosome 11 in humans. Diabetes. 1981;30:267-270.
51. Bell GI, Selby M, Rutter WJ. The highly polymorphic region near the human insulin gene is composed of simple tandemly repeating sequences. Nature. 1982;295:31-35.
52. Bennett ST, Lacassen AM, Gough SCL, et al. Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nat Genet. 1995;9:284-292.
53. Kennedy GC, German MS, Rutter WJ. The minisatellite in the diabetes susceptibility locus IDDM2 regulates insulin transcription. Nat Genet. 1995;9:293-298.
54. Bell GI, Horita S, Karam JH. A polymorphic locus near the human insulin gene is associated with insulin-dependent diabetes mellitus. Diabetes. 1984;33:176-183.
55. Rotwein PS, Chirgwin J, Province M, et al. Polymorphism in the 5′ flanking region of the human insulin gene: a genetic marker for non-insulin-dependent diabetes. N Engl J Med. 1983;308:65-71.
56. Ober C, Wason CJ, Andrew K, Dooley S. Restriction fragment length polymorphisms of the insulin gene hypervariable region in gestational onset diabetes mellitus. Am J Obstet Gynecol. 1987;157:1364-1368.
57. McGinnis RE, Spielman RS. Insulin gene 5′ flanking polymorphism. Length of class 1 alleles in number of repeat units. Diabetes. 1995;44:1296-1302.
58. Gartside P, Laskarzewski P, Khoury P, Tyroler H. High-density lipoprotein cholesterol and Whites: potential ramifications for coronary disease. Am Heart J 1984;108(3):815-825.
59. Gillum R. Cardiovascular disease in the United States: an epidemiologic overview. In: Saunders E, ed. Cardiovascular Disease in Blacks. Philadelphia, Pa: F A Davis; 1991:3-16.
60. Tyroler H. Serum lipoproteins as risk factors: recent epidemiologic studies in individuals with and without prevalent cardiovascular disease. Eur Heart J. 1990;11 (suppl H):21-25.
61. Rhoads G, Dahlen G, Berg K, Morton N, Dannenberg A. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 1986; 256(18):2540-2544.
62. Dahlen GH, Slunga L, Holmlund G, Lango A, Lindblom B. Lp(a) lipoprotein and HLA-DR genotype in early coronary artery disease. Eur J Immunogenet. 1993;20:95-102.
63. Dahlen GH, Slunga L, Lindblom B. Importance of Lp(a) lipoprotein and HLA geno-types in atherosclerosis and diabetes. Clin Genet. 1994;46:46-56.
64. Dahlen GH, Boman J, Birgander LS, Lindblom B. Lp(a) lipoprotein, IgG, IgA, and gM antibodies to Chlamydia pneumoniae and HIA class II genotype in early coronary artery disease. Atherosclerosis. 1995;114:165-174.
65. Jonasson L, Eriksson T, Dahle'n GH, Lindblom B. Lipoprotein(a) and HLA-DRB1 and -DQB1 genes in coronary artery disease. Atherosclerosis. 1997;133:111-114.
66. Seed M, Hoppichler F, Reaveley D, et al. Relation of serum lipopoprotein (a) concentration and apolipoprotein (a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med. May 1990:1494-1499.
67. Kraft H, Linggenhel A, Pang R, et al. Frequency distribution of apolipoprotein (a) kringle IU repeat alleles and their effects on lipoprotein (a) levels in Caucasian, Asian, and African populations: the distribution of null alleles is non-random. Eur J Hum Genet. 1996;4(2):74-87.
68. Kraft H, Wingdegger M, Menzel M, Utermann G. Significant impact of the *93 C/T polymorphisms in the apolipoprotein (a) gene on Lp(a) concentrations in African but not in Caucasians: confounding effect of linkage disequilibrium. Hum Mol Genet. 1998;7(2): 257-264.
69. Trommsdorff M, Chi K, Lingenhel S, et al. A pentanucleotide repeat polymorphisms in the 5 prime control region of the apolipoprotein (a) gene is associated with lipoprotein (a) plasma concentrations in Caucasians. J Clin Invest. 1995;96(1):150-157.
70. Ameemiya H, Arinami T, Kikuchi S, et al. Apolipoprotein (a) and pentanucleotide repeat polymorphisms are associated with the degree of atherosclerosis in coronary heart disease. Atherosclerosis. 1996;123(1-2):181-191.
71. Mooser M, Scheer D, Marcovine S, et al. The Apo (a) gene is the major determinant of variation in plasma Lp(a) levels in African Americans. Am J Hum Genet. 1997;61:402-417.
72. Woodhouse S. Coronary heart disease: new guidelines for determining risk and prevention. Advance Lab. January 2002:27-32.
73. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 111). JAMA. 2001;285(19):2486-2497.
74. Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts? Circulation. 2003;108(13):1546-1551.
75. Ford E, Giles W, Dietz W. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002; 287(3):356-359.
76. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens. 1992;39: 225-235.
77. Edwards A, Hammond HA, Jin L, Caskey T, Chakraborty R. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics. 1992;12:241-253.
78. Perry RT, Collins JS, Harrell LE, Acton RT, Go RC. Investigation of association of 13 polymorphisms in eight genes in southeastern African-American Alzheimer disease patients as compared to age-matched controls. Am J Med Genet. 2001;105(4):332-342.
79. Jongeneel V, Briant L, Irina A, et al. Extensive genetic polymorphism in the human tumor necrosis factor á region and relation to extended HLA haplotypes immunology. Proc Natl Acad Sci. 1991;88:9717-9721.
80. Pociot F, Briant L, Jongeneel C, et al. Association of tumor necrosis (TNF) and class II major histocompability complex alleles with the secretion of TNF Alpha and TNF Beta by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol. 1993;23:224.
81. Monos D, Malek K, Udalova I, et al. Genetic polymorphism of the human tumor necrosis factor region in insulin-dependent diabetes mellitus linkage disequilibrium of TNA ab microsatellite alleles with HLA halotypes. Hum Immunol. 1995;44:70-79.
82. Garcias-Merino A, Alper C, Usuka K, et al. Tumor necrosis factor (TNF) micro-satellite halotypes in relation to extended halotypes, susceptibility to disease associated with the major histocompatibiliry complex and TNF secretion. Hum Immunol. 1996;50:11-21.
83. Kulkarni K, Segrest J. Quantification of cholestrol in lipoprotein classes by the VAPII method. J Lipid Res. 1994;40:1123-1134.
84. Matthews D, Hosker A, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis and assessment: insulin resistance and â-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28:412-419.
85. Wing R, Matthews K, Kuller L, Smith D, Becker D, Plantinga P. Environmental and familial contributions to insulin levels and change in insulin levels in middle-aged women. JAMA. 1992;268(14):1890-1895.
86. Weir B. Introduction to Statistical Genetics. An ASA LEATNSTAT Course. George Washington University, Alexandria Graduate Education Center, February 23, 1998.
87. Agresti A. A survey of exact inference for contingency tables. Stat Sci. 1992;7(1):131-177.
88. Caro J. Insulin resistance in obese and non-obese man. J Clin Endocrinol Metab. 1991; 73(4):691-695.
89. Valdez R, Howard B, Stern M, Haffner S. Apolipoprotein E polymorphism and insulin levels in biethnic populations. Diabetes Care 1995;18(7):992-1000.
90. Chen Q, Reis SE, Kammerer CM, et al. APOE polymorphism and angiographic coronary artery disease severity in the Women's Ischemia Syndrome Evaluation (WISE) Study. Atherosclerosis. 2000;169(1):159-167.
91. Moliterno D, Jokinen E, Miserez A, et al. No association between plasma lipoprotein (a) concentrations and the presence or abscence of coronary atherosclerosis in African Americans. Arterioscler Thromb Vasc Biol. 1995; 15(7):850-855.
92. Gaw A, Boerwinkle E, Cohen J, Hobbs H. Comparative analysis of the apo(a) gene, apo(a) gylcoprotein, and plasma concentrations of Lp(a) in three ethnic groups, evidence for no common nll allele at the apo(a). J Clin Invest. 1994;93:2526-2534.
93. Hayden S, Eckardstein A, Schulte H, Schneider K, Assmann G. Raised lipoprotein(a) in hypercholesterolemic Black students compared to age-matched Whites in North and South Carolina. Int J Epidemiol. 1994;23: 301-306.
94. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003; 289(1):76-79.
95. Ninomiya J, L'Italien G, Criqui M, Whyte J, Garnst A, Chen R. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation. April 2003. Available at: http://www.circulationaha.org.
96. Kubaszek A, Pihlajamaki J, Komarovski V, et al. Promoter polymorphisms of the TNF-a (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes. Diabetes. 2003;52: 1872-1876.
97. Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes. 2003;27:S53-S55.
98. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity, and diabetes. Trends Immunol. 2004;25(1):4-7.